# Dynavax Technologies Corp

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Dynavax Technologies Corp).

## Overview

Dynavax Technologies Corp. is a U.S.-based biopharmaceutical company focused on vaccines and adjuvant technology for infectious diseases. Its commercial business is anchored by HEPLISAV-B, a hepatitis B vaccine sold primarily in the United States, while it also develops and monetizes CpG 1018 adjuvant through collaborations and research partnerships.

## Products & services

• HEPLISAV-B hepatitis B vaccine
• CpG 1018 adjuvant supply
• Vaccine development pipeline
• Commercialization and co-promotion partnerships
• Research collaborations for vaccine candidates

- **Commercial vaccine products** (95%) — Revenue-generating vaccine products sold to healthcare channels, led by HEPLISAV-B.
- **Adjuvant supply** (3%) — CpG 1018 adjuvant supplied to partners for use in vaccine development and commercialization.
- **Other revenue and government agreements** (2%) — Other revenue primarily tied to the DoD agreement and similar non-product arrangements.

- HEPLISAV-B adult hepatitis B vaccine
- CpG 1018 adjuvant for vaccine partners
- Vaccine candidate development
- Commercial distribution and co-promotion deals
- Research collaboration agreements

## Customers

Dynavax sells mainly into U.S. healthcare distribution channels, where HEPLISAV-B is purchased through vaccine distributors, providers, and other healthcare buyers serving adult immunization demand. The company also works with pharmaceutical and biotechnology partners that buy or license CpG 1018 adjuvant and related development rights. Government-related counterparties, including the DoD, contribute a smaller but recurring source of other revenue.

- **U.S. vaccine distribution channels** (primary) — Distributors, clinics, and provider networks that purchase HEPLISAV-B for adult hepatitis B immunization.
- **Healthcare providers** (primary) — Physicians and other providers that administer HEPLISAV-B and influence uptake through clinical adoption.
- **Pharmaceutical and biotechnology partners** (secondary) — Partners that buy or collaborate on CpG 1018 adjuvant and vaccine development programs.
- **Government and defense customers** (secondary) — Public-sector counterparties, including the DoD, that generate other revenue through supply or collaboration agreements.
- **International commercialization partners** (emerging) — Partners used to access markets such as Germany and other non-U.S. geographies where direct sales are limited.

- Healthcare providers and vaccine distributors buying HEPLISAV-B
- Adult immunization channels seeking hepatitis B vaccination
- Pharma/biotech partners using CpG 1018 adjuvant
- Government counterparties such as the DoD
- International partners for market entry and distribution

## Geography

Dynavax’s revenue base is concentrated in the United States, where HEPLISAV-B is commercialized and where most product revenue is generated. The company has limited non-U.S. product revenue and has stated it does not currently anticipate meaningful non-U.S. sales in the near future, though it has used partners to support entry into markets such as Germany. Geography matters because the business depends on U.S. vaccine demand, provider access, and channel execution, while international expansion remains selective and partnership-driven.

- United States is the core commercial market for HEPLISAV-B
- Non-U.S. product revenue is currently limited
- Germany has been used as a partnered market entry example
- DoD-related other revenue is U.S.-based
- Future international growth likely depends on partners

## Strategy

Dynavax is focused on maximizing HEPLISAV-B utilization, expanding its vaccine portfolio, and monetizing CpG 1018 through commercial and research collaborations. The company is also trying to broaden market access without overbuilding fixed commercial infrastructure, which is why partnerships remain important for international expansion and adjuvant commercialization.

- **Increase HEPLISAV-B adoption in the U.S.** (short-term) — The vaccine is the main revenue engine, so share gains and pricing discipline drive near-term growth.
- **Broaden the vaccine pipeline** (medium-term) — A larger portfolio reduces dependence on a single product and creates longer-term growth options.
- **Expand CpG 1018 collaborations** (medium-term) — Partnering can generate revenue without requiring full commercial buildout in every market.

- Grow HEPLISAV-B market share in the U.S.
- Expand vaccine pipeline using CpG 1018 technology
- Use partnerships to enter new markets efficiently
- Monetize adjuvant supply through collaborations
- Maintain commercial infrastructure without overextending costs

## Risks

Dynavax is highly dependent on the commercial success of HEPLISAV-B, so adoption, pricing, and competitive pressure can materially affect results. The company also faces execution risk around salesforce buildout, provider access, manufacturing/third-party supply, and the ability to secure acceptable partnership terms for new markets. As a vaccine company, it is also exposed to reimbursement, regulatory, and seasonality-related demand swings.

- **Dependence on HEPLISAV-B** [high] — HEPLISAV-B is the only revenue-producing product, so any slowdown in adoption or pricing directly impacts revenue and operating leverage.
- **Commercial execution risk** [high] — The company must recruit and retain sales staff, access providers, and compete in established vaccine channels to sustain growth.
- **Partner dependence for expansion** [medium] — International growth and some adjuvant monetization depend on third-party collaboration terms and partner execution.
- **Supply and manufacturing disruption** [high] — Reliance on third-party manufacturers or logistics can cause missed deliveries, penalties, or lost revenue.
- **Reimbursement and payer pressure** [medium] — Coverage and pricing decisions by payors can affect commercial uptake and net realized revenue.

- HEPLISAV-B concentration creates product dependence risk
- Competition in hepatitis B vaccines can limit uptake
- Salesforce and provider access are critical to commercialization
- Third-party manufacturing or delivery failures can disrupt supply
- Reimbursement and payer coverage can constrain demand

## Accounting

Dynavax’s reported revenue is sensitive to net sales estimates, especially returns, chargebacks, discounts, rebates, and other fees on HEPLISAV-B. The company also has seasonality in vaccine demand, with fourth-quarter sales typically weaker than third quarter, which can distort quarter-to-quarter comparisons. Investors should also watch reserve estimates, collaboration revenue timing, and any changes in assumptions that affect net product revenue.

- **Net product revenue estimates** — Affects HEPLISAV-B net revenue and gross-to-net margin
- **Seasonality** — Quarterly revenue and margin volatility
- **Reserve adjustments** — Can create one-time uplift in reported sales
- **Other revenue recognition** — Affects comparability of total revenue

- HEPLISAV-B revenue is recorded net of returns and rebates
- Reserve estimates can move revenue when return rates change
- Vaccine seasonality affects quarterly comparability
- Other revenue includes DoD-related agreement revenue
- Collaboration revenue timing may vary with partner milestones

---

*Last updated: 2026-04-28T20:01:18.821964+00:00*